Search Results for "Value"

A closer look at three of PhRMA’s most cited talking points.

Not all approaches are suited to meeting policy makers and health plans’ goals of managing specialty drugs based on their value. Researchers conducted a qualitative study with Blue Cross Blue Shield plans interested in implementing value-based specialty pharmacy management to observe the plans’ objectives, strategies, and factors influencing their ability to execute on these strategies.

The administration has proposed a loophole in the Medicaid Best Price rules that would dismiss linking the drug's effectiveness to its price.

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Biosimilars require extensive, expensive, and time-consuming human testing prior to market entry, a process vastly different than generics. So why are we still doing them?

The Drug Pricing Lab engaged Milliman to conduct an independent analysis of the Production Plus Profit Pricing (P-quad) policy proposal. The Milliman analysis estimates the projected spending on U.S. biologic and biosimilar drugs under a referent scenario where there is no biosimilar entry or competition, the existing ‘status quo’ scenario under the current biosimilar environment, and the Drug Pricing Lab’s P-quad policy proposal. 

This report was commissioned by Drug Pricing Lab.

The goal of a QALY is to figure out how much any given drug is worth to a society so that we, as a society, have a benchmark to evaluate the price of pharmaceutical products.

Research Data Analyst, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Financial and Biopharma Industry Analyst, Drug Pricing Lab, Memorial Sloan Kettering Cancer Center

Program Director and Senior Health Economist, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Industry sponsorship of patient advocacy groups opposing the QALY threatens to undermine not just the QALY but also an objective analysis of policy decisions.

Several approaches that rewire existing reimbursement conventions as alternatives to facilitate ISP are proposed.

Steep increases in prices and spending on prescription drugs in the United States have triggered public outrage and questions about their value.

Value-based pricing has emerged as an alternative to prices determined by what the market will bear. But which agreements are truly "value-based"?

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

U.S. prices of common cardiovascular drugs are not consistent with the cost-effectiveness evidence.

The Drug Pricing Lab responds to the Trump Administration’s Request for Information on lowering drug prices with a summary of our findings.

A taxonomy of the features that make a payment model truly value-based.

Pharmaceutical manufacturers push for adoption of outcomes-based contracting as a means of achieving a value-based price, but such contracts are ill-suited to do so.

Three policy papers released by Health Affairs in collaboration with the Drug Pricing Lab and the Commonwealth Fund cover fundamental prescription drug pricing problems.

Drug Pricing Lab op-ed in STAT News discusses indication-specific pricing of Kymriah.

Dana Goldman and Darius Lakdawalla look to Major League baseball to explain the drug pricing problem.